Kevin Pojasek, Enara CEO
January 12, 2021 07:09 AM EST
Deals

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

Jason Mast

Editor

A year af­ter rais­ing $17.5 mil­lion for a plat­form to search for so-called “dark anti­gens” lurk­ing in tu­mors, Enara Bio has nabbed a buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times